Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of Therapies & ASP by Therapy Type & Route of Administration The global hormone replacement therapy market will witness a robust CAGR of 7.83%, valued at $24.97 billion in 2021, expected to appreciate and reach $49.25 billion by 2030, confirms Strategic Market Research. Hormone replacement therapy (HRT) is a treatment procedure for replacing and replenishing hormones in the human body that are at inadequate levels compared to those required for normal physiology. The most well-known application of HRT is in the treatment of menopause symptoms. In other words, Hormone replacement therapy is a medical procedure in which patients are given hormones to replace naturally occurring hormones or augment naturally occurring ones that are missing. In the case of females, this treatment is used to restore the hormone levels in women who are at the stage of menopause, allowing the body to operate normally. Hormone replacement therapy (HRT) uses hormones to replace natural hormones when the body's production is insufficient. For instance, hormone replacement therapy is usually given to thyroid patients and human growth hormone patients. Furthermore, HRT was often administered to menopausal women to alleviate indications such as night sweats, hot flushes, sleep disturbances, psychological and genito-urinary disorders (urinary frequency and vaginal dryness), and the prevention of osteoporosis. In addition, a survey of 2,000 American women aged 30 to 60 indicated that approximately 47% of the surveyed population experienced the symptoms of hormonal imbalance in 2019. Menopause is the most frequently reported consequence of age-related hormonal changes. It often begins around the age of 50 in women around the world. By the age of 50, the levels of oestrogen and progesterone produced by women significantly decrease. The pituitary gland compensates for the decline in oestrogen and progesterone production by increasing the output of follicle-stimulating hormone. Drivers The rise in prevalence of menopausal illness and increased awareness of post-menopausal difficulties among women are two significant factors driving the worldwide HRT market. The hormone replacement therapy market trend is being driven by a large increase in the incidence rate of hormonal abnormalities in newborns, adults, and the elderly. Moreover, disease like The Prader-Willi syndrome (PWS) affects one out of every 15,000 babies. Low-Dosevaginal estrogen therapy, topical estrogen therapy, hysterectomy with bilateral salpingo-oophorectomy, Systemic hormone therapy, and Bioidentical hormone replacement therapy are all the factors that drive the market globally. Restraints During the projected period, unfavorable effects of hormone replacement therapy are expected to restrain market expansion. The high expense of hormone replacement therapy and the risk of acquiring cancer from HRTs are expected to stifle global market growth. Risks involved in hormone replacement therapy include Heart disease, Stroke, Blood clots, and Breast cancer which are expected to restrain the market. Key Opportunity The need for bioidentical hormone replacement therapy and the use of telemedicine for hormone replacement therapy are projected to give a lucrative opportunity for the global hormone replacement therapy market to expand in the near future. Market Analysis Of Different Segments Covered in the Report By Route Of Administration Oral Parenteral Others Hormone Replacement Therapy Market By Therapy Type Estrogen Hormone Replacement Therapy Human Growth Hormone Replacement Therapy Thyroid Hormone Replacement Therapy Testosterone Hormone Replacement Therapy Progestogen Hormone Replacement Therapy By Indication Menopause Hypothyroidism Male Hypogonadism Growth Hormone Deficiency Others By Region North America United States Canada Mexico Europe Germany France Italy Switzerland UK Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Brazil Israel South Africa Saudi Arabia Rest of LAMEA Based on Route Of Administration, the oral market segment accounted for the largest proportion of the hormone replacement treatment market in 2020 and is predicted to increase at the quickest rate over the forecast period. This is because oral administration of testosterone medications is highly favored, and oral medication is the most prevalent form of oestrogen replacement therapy. In terms of therapy type, estrogen hormone replacement therapy was the market leader in 2020. This is due to women's increased usage of estradiol products to help them maintain hormonal balance after menopause or hysterectomy. Dryness, burning, itching, and pain during intercourse are some of the vaginal symptoms of menopause that can be alleviated by oestrogen replacement hormone therapy. Estrogen can be taken as a Estrogenpill, gel, Estrogen patch, lotion, or spray. It has a good success rate in treating menopausal night sweats and hot flashes, around 45 percent of women aged 40 to 60 reported seeking medical advice on the benefits and drawbacks of utilizing hormone replacement therapy (HRT) after menopause. Menopause is predicted to expand at the quickest rate in terms of indication from 2021 to 2028, as there is a great advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years. In accordance to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause every day. According to World Health Organisation (WHO), around 15 million neonates are born prematurely, with approximately 85% of these children being underdeveloped. Hormone treatment is used in adults to treat disorders like short bowel syndrome and pituitary tumors. The North American market dominated the global hormone replacement therapy market in 2019 due to the rise in manufacturer’s release of various generic hormone replacement therapy medicines, an increase in the target population, and advances in drug delivery technologies, as well as the creation of new formulations. Also, because of the rising public awareness, the hormone replacement treatment market in Asia Pacific is expected to grow quickly in the future years. Emerging countries such as Japan, India, and China will play a significant role in market expansion. According to the NIH(National Institutes of Health), half of the postmenopausal women have used HRT at least once. In 2014, more than 2.5 million Americans received testosterone treatment, according to the American Academy of Family Physicians. In accordance to NIH, about half of all postmenopausal women in the United States had hormone replacement therapy (HRT) at some point in their life. In addition, roughly 1.3 million American women will enter the menopause phase each year by 2021, according to a study published in Statpearls. According to studies conducted by organizations such as Rose Research, the North American Menopause Society (NAMS), and Therapeutic MD, approximately one million women in the United States are currently using hormone replacement therapy, which is expected to rise to 2.5 million in the near future. According to a study published in the Journal of Menopausal Medicine in 2020, about 75 percent of women experience menopause symptoms between the ages of 45 and 55, resulting in decreased self-esteem. According to the World Population Ageing 2019 study, women will account for 54 percent of the global population aged 65 and over by 2050, with a life expectancy at birth of 74.7 years in 2019. According to the American Thyroid Association (ATA), more than 12% of the US population is expected to have a thyroid issue during their lifetime, and nearly 20 million Americans are impacted by thyroid illness each year. As a result of the significant prevalence of thyroid hormone imbalance among the people in the United States, the studied market in the region is predicted to grow. Hormone Replacement Therapy Market Competitive Landscape Analysis Abbott Laboratories Bayer Ag. Eli Lily And Company Hoffmann-La Roche Ltd. (Genentech, Inc.) Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.) Merck Kgaa Mylan N.V. (Viatris Inc.) Novartis International Ag Novo Nordisk A/S Pfizer Inc. Hormone Replacement Therapy Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 24.97 billion The revenue forecast in 2030 USD 49.25 billion Growth rate CAGR of approximately 7.839% The base year for estimation 2021 Historical data 2015 – 2019 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Route Of Administration, By Therapy Type, By Indication, By Region By Route Of Administration Oral, Parenteral, Others By Therapy Type Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy By Indication Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others By Region North America, Asia-Pacific, Europe, LAMEA Country Scope United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa Company Usability Profiles Abbott Laboratories, Bayer Ag., Eli Lily And Company, Hoffmann-La Roche Ltd. (Genentech, Inc.), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S, Pfizer Inc. Recent Developments On August 16th, 2022, Akorn announced that it had successfully received FDA approval for launching its Generic-Cetrorelix Acetate in the form of Injection (0.25 mg quantity). Cetrorelix is one of the most effective chemicals used in hormone replacement therapy as it totally blocks the adverse impacts of a natural hormone, known as GnRH or gonadotropin-releasing hormone. During the treatment process of ovarian stimulation, premature ovulation can lead to the formation of eggs that are unsuitable for fertilization. The Cetrorelix Acetate present in the Injection blocks such kind of premature ovulation. In December 2020, The US FDA approved Myovant Sciences' Orgovyx (relugolix). Orgovyx (relugolix) is an orally administered treatment that prevents the pituitary gland from producing luteinizing hormone and follicle-stimulating hormone, decreasing the amount of testosterone produced by the testicles. This aids in the treatment of advanced prostate cancer in adults. In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which will help Bayer to expand its women's medicine pipeline by including menopausal treatment in its portfolio. In August 2020, the FDA (US Food and Drug Administration) authorized Sogroya (somapacitan), a human growth hormone (HGH) therapy for adults with growth hormone insufficiency that is administered once a week via injection under the skin. As a result, the region's analyzed market is projected to be driven by the high trend of product approvals. The Key Products that the Market Leaders Develop Name of the product Function Key Players THYROCAB It is used in curing hyperthyroidism Abbott Laboratories ANGELIQ It is used to reduce menopause symptoms Bayer Inc. Adakveo It is used to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients. Novartis International Ag Frequently Asked Question About This Report What is the hormone replacement therapy market growth? The global hormone replacement therapy market is expected to grow at a compound annual growth rate (CAGR) of 7.839% from 2021 to 2030 to reach USD $ 49.25 billion by 2030. How big is the hormone replacement therapy market size? The global hormone replacement therapy market size was $24.97 billion in 2021 and is predicted to reach $49.25 billion by 2030, with a CAGR of 7.83%. Which is the leading Indication for Hormone Replacement Therapy Market? According to indication, the menopausal segment would grow at the quickest rate throughout the projected period, due to an increasing advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years. Who are the key players majorly operating in the Hormone Replacement Therapy Market? The key players majorly operating in the Hormone Replacement Therapy Market areAbbott Laboratories, Bayer Ag.Eli Lily And Company, Pfizer Inc., Hisamitsu Pharmaceutical Co., Hoffmann-La Roche Ltd. (Genentech, Inc.), Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S, Which market segment is leading the Therapy Type category of the market? In terms of therapy type, oestrogen hormone replacement therapy was the market leader in 2021. Which is the leading Route of Administration for market? The oral category accounted for the greatest proportion of the market in 2021 Sources https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf https://www.who.int/news-room/fact-sheets/detail/preterm-birth https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963523/ https://www.statpearls.com/ArticleLibrary/viewarticle/27522 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830366/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Hormone Replacement Therapy Market 4.2.1 Global market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global market, by region, 2021 - 2030 (USD Million) 4.4 By Therapy Type Business Analysis 4.4.1 Global market, By Therapy Type, 2021 - 2030 (USD Million) 4.5 By Indication Business Analysis 4.5.1 Global market, By Indication, 2021 - 2030 (USD Million) 4.6 Route Of Administration Business Analysis 4.6.1 Global market, By Route Of Administration, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 market PEST analysis 4.9.2 market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Route Of Administration Analysis 5.11.1. Trends in Route Of Administration (2014-2021) 5.11.2. Trends in Route Of Administration (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Therapy Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Therapy Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Estrogen 7.3.1. Estrogen market, 2021 - 2030 (USD Million) 7.4. Human Growth 7.4.1. Human Growth market, 2021 - 2030 (USD Million) 7.5. Thyroid 7.5.1. Thyroid market, 2021 - 2030 (USD Million) 7.6. Testosterone 7.6.1. Testosterone market, 2021 - 2030 (USD Million) 7.7. Progestogen 7.7.1. Progestogen market, 2021 - 2030 (USD Million) 8. Global Market: By Indication Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Menopause 8.3.1. Menopause market, 2021 - 2030 (USD Million) 8.4. Hypothyroidism 8.4.1. Hypothyroidism market, 2021 - 2030 (USD Million) 8.5. Male Hypogonadism 8.5.1. Male Hypogonadism market, 2021 - 2030 (USD Million) 8.6. Growth Hormone Deficiency 8.6.1. Growth Hormone Deficiency market, 2021 - 2030 (USD Million) 8.7. Others 8.7.1. Others market, 2021 - 2030 (USD Million) 9. Global Market: By Route Of Administration Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Oral 9.3.1. Oral market, 2021 - 2030 (USD Million) 9.4. Parenteral 9.4.1. Parenteral market, 2021 - 2030 (USD Million) 9.5. Others 9.5.1. Others market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America market, by By Therapy Type, 2021 - 2030 (USD Million) 10.1.2. North America market, by By Indication, 2021 - 2030 (USD Million) 10.1.3. North America market, by Route Of Administration, 2021 - 2030 (USD Million) 10.1.4. North America market, by Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. market, by By Therapy Type, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S. market, by By Indication, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S. market, by Route Of Administration, 2021 - 2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada market, by By Therapy Type, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada market, by By Indication, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada market, by Route Of Administration, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe market, by By Therapy Type, 2021 - 2030 (USD Million) 10.2.2. Europe market, by By Indication, 2021 - 2030 (USD Million) 10.2.3. Europe market, by Route Of Administration, 2021 - 2030 (USD Million) 10.2.4. Europe market, by country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. market, by By Therapy Type, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. market, by By Indication, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. market, by Route Of Administration, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany market, by By Therapy Type, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany market, by By Indication, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany market, by Route Of Administration, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France market, by By Therapy Type, 2021 - 2030 (USD Million) 10.2.4.3.2. France market, by By Indication, 2021 - 2030 (USD Million) 10.2.4.3.3. France market, by Route Of Administration, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe market, by By Therapy Type, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe market, by By Indication, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific market, by By Indication, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.4.1.2. China market, by By Indication, 2021 - 2030 (USD Million) 10.3.4.1.3. China market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.4.2.2. India market, by By Indication, 2021 - 2030 (USD Million) 10.3.4.2.3. India market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan market, by By Indication, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea market, by By Indication, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea market, by Route Of Administration, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC market, by By Therapy Type, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC market, by By Indication, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC market, by Route Of Administration, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America market, by By Therapy Type, 2021 - 2030 (USD Million) 10.4.2. Latin America market, by By Indication, 2021 - 2030 (USD Million) 10.4.3. Latin America market, by Route Of Administration, 2021 - 2030 (USD Million) 10.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil market, by By Therapy Type, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil market, by By Indication, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil market, by Route Of Administration, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico market, by By Therapy Type, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico market, by By Indication, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico market, by Route Of Administration, 2021 - 2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America market, by By Therapy Type, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America market, by By Indication, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America market, by Route Of Administration, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA market, by By Therapy Type, 2021 - 2030 (USD Million) 10.5.2. MEA market, by By Indication, 2021 - 2030 (USD Million) 10.5.3. MEA market, by Route Of Administration, 2021 - 2030 (USD Million) 10.5.4. MEA market, by Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 Abbott Laboratories 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. Product Portfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. Bayer Ag 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. Eli Lily And Company 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. Hoffmann-La Roche Ltd. (Genentech, Inc.) 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.) 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Merck Kgaa 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Mylan N.V. (Viatris Inc.) 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Novartis International Ag 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Novo Nordisk A/S 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Pfizer Inc. 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development List of Tables (53 Tables) TABLE 1. MARKET, By Therapy Type, 2021-2030 (USD Million) TABLE 2. MARKET FOR Estrogen , BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Human Growth , BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Thyroid , BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Testosterone , BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Progestogen , BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET, By Indication, 2021-2030 (USD Million) TABLE 8. MARKET FOR Menopause, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Hypothyroidism, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Male Hypogonadism, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Growth Hormone Deficiency, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Oral, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Parenteral, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA MARKET, By Therapy Type, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA MARKET, By Indication, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 22. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 23. EUROPE MARKET, By Therapy Type, 2021-2030 (USD Million) TABLE 24. EUROPE MARKET, By Indication, 2021-2030 (USD Million) TABLE 25. EUROPE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC MARKET, By Therapy Type, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC MARKET, By Indication, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 30. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. LAMEA MARKET, By Therapy Type, 2021-2030 (USD Million) TABLE 32. LAMEA MARKET, By Indication, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD Million) TABLE 34. Abbott Laboratories: COMPANY SNAPSHOT TABLE 35. Abbott Laboratories: OPERATING SEGMENTS TABLE 36. Bayer Ag: COMPANY SNAPSHOT TABLE 37. Bayer Ag: OPERATING SEGMENTS TABLE 38. Eli Lily And Company: COMPANY SNAPSHOT TABLE 39. Eli Lily And Company: OPERATING SEGMENTS TABLE 40. Hoffmann-La Roche Ltd. (Genentech, Inc.): COMPANY SNAPSHOT TABLE 41. Hoffmann-La Roche Ltd. (Genentech, Inc.): OPERATING SEGMENTS TABLE 42. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.): COMPANY SNAPSHOT TABLE 43. Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.): OPERATING SEGMENTS TABLE 44. Merck Kgaa: COMPANY SNAPSHOT TABLE 45. Merck Kgaa: OPERATING SEGMENTS TABLE 46. Mylan N.V. (Viatris Inc.): COMPANY SNAPSHOT TABLE 47. Mylan N.V. (Viatris Inc.): OPERATING SEGMENTS TABLE 48. Novartis International Ag: COMPANY SNAPSHOT TABLE 49. Novartis International Ag: OPERATING SEGMENTS TABLE 50. Novo Nordisk A/S: COMPANY SNAPSHOT TABLE 51. Novo Nordisk A/S: OPERATING SEGMENTS TABLE 52. Pfizer Inc: COMPANY SNAPSHOT TABLE 53. Pfizer Inc: OPERATING SEGMENTS List of Figures (21 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Hormone Replacement Therapy, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Hormone Replacement Therapy, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Indication, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Route Of Administration, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Therapy Type, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Estrogen to Witness Higher CAGR in Market for Therapy Type Segment during Forecast Period. Figure 16 Oral to Witness Higher CAGR in Market for Route Of Administration Segment during Forecast Period. Figure 17 Menopause to Witness Higher CAGR in Market for Indication Segment during Forecast Period. Figure 18 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview